AI Entity commercializes first AI-powered immune intelligence platform for precision medicine
Eparinges, Switzerland, March 5, 2026 /PRNewswire/ — Novigenix SA, a leader in immunotranscriptomic diagnostics, today officially spins out Novigenics AIis a new precision medicine company working to transform treatment development through AI-powered immune intelligence.
Strategic separation to unlock two high-growth markets
PMWC 2026 Team Photo
The new AI spinout will separate Novigenix’s colorectal cancer (CRC) screening business from its rapidly growing AI-driven biopharmaceutical and precision medicine platforms, allowing each company to pursue focused go-to-market strategies, customized capital structures, and clear partnership paths.
Novigenics SA We continue to evolve our CRC screening portfolio, including Colox® and ColoxNGS® Distributed through Diagnosuite™ and clinical testing partners.
Novigenics AI Exclusively commercialize LITOSeek® A platform for clinical applications in biopharmaceuticals, biotechnology, and precision medicine around the world.
“Oncology is only half the story. Delivering truly personalized medicine requires understanding how a patient’s immune system responds to disease and treatment. Spinning out Novigenix AI will enable laser-focused investments, faster market penetration, and greater value creation for our shareholders and biopharmaceutical partners. This is the beginning of a new era in immune intelligence.” said Brian B. Hashemi, Ph.D., MBA, CEO and Chairman of Novigenix AI.
Lito seek®
Dr. Milo Venturi, a member of Novigenix AI’s board of directors and a veteran of precision medicine and drug development, said: “The development of new therapies is often compromised by heterogeneous patient responses, suboptimal clinical efficacy, and severe grade 3-4 adverse events. Novigenix AI’s AI-enabled liquid biopsy solution provides longitudinal visibility into patient immune function, helping translational medicine teams effectively address these challenges.”
At the core of Novigenix AI: Lito seek®the first AI-powered immune intelligence platform designed to longitudinally decipher systemic immune responses from simple blood samples. This platform transforms complex liquid biopsy data into clinically actionable insights by analyzing immune-derived RNA using advanced machine learning. The platform supports real-time tracking of immune health, treatment response, resistance mechanisms, and risk of adverse events by providing:
- ImmunoPharmacoDynamic (ImmunoPD™) response markers for long-term monitoring
- Mechanistic insights into drug action and resistance
- Predictive biomarkers of treatment response and resistance
- Early indicators of immune-related toxicity and adverse events
- Digital cytometry and cell deconvolution using machine learning
- Scalable cloud-based SaaS analytics integration
Lito seek® It is ISO 13485 certified and built for standardized and reproducible deployment across biopharmaceutical clinical trial and research environments with secure cloud analytics infrastructure and distributed data generation capabilities, ensuring global readiness from day one.
Strong commercial traction and proven partnerships
Novigenix AI launches with established revenues and a proven commercial track record. Although initial commercialization is focused on oncology, the platform’s immune intelligence capabilities are extending into the realm of autoimmune, neurological, and other immune-mediated diseases, creating opportunities for long-term expansion across multiple therapeutic categories.
About Novigenix AI
Novigenix AI is a Swiss-based precision medicine company pioneering AI-powered immune intelligence. The company’s LITOSeek® platform analyzes blood RNA to generate predictive and mechanistic insights that guide therapy development, patient stratification, and clinical decision-making. The company is ISO 13485 certified and operates with global reach across the United States and Europe.
www.novigenix.com
Photo – https://mma.prnewswire.com/media/2926409/Novigenix_AI_PMWC_2026_Team_Photo.jpg
